Discovery20
Latest Headlines
Trending stories — sign in for a personalized feed
Today
Afya Limited Announces First-Quarter 2026 Financial Results
an hour ago
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
an hour ago
V2X, INC. ANNOUNCES PRICING OF OFFERING OF APPROXIMATELY 2.0 MILLION SHARES OF COMMON STOCK IN SECONDARY OFFERING BY VERTEX AEROSPACE
an hour ago
Genco Shipping & Trading Limited Issues Statement Regarding Diana’s Unsubstantiated Assertions
an hour ago
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
an hour ago
MP Materials Reports First Quarter 2026 Results
2 hours ago
Greenfire Resources Reports Voting Results from 2026 Annual Meeting of Shareholders
2 hours ago
Gamehost to Hold Special Meeting on June 11, 2026 to Approve Sale Transaction to Pure Casino
2 hours ago
Yesterday
Goldman Sachs BDC, Inc. Reports March 31, 2026 Financial Results and Announces Second Quarterly 2026 Base Dividend of $0.32 Per Share.
2 hours ago
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 hours ago
Journey Energy Inc. Reports Its First Quarter 2026 Financial and Operating Results
2 hours ago
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
3 hours ago
Badger Announces Pricing of C$300 Million Senior Unsecured Notes
3 hours ago
IREN Secures $3.4bn AI Cloud Contract with NVIDIA
3 hours ago
Perseus Mining Appoints Chief Operating Officer
3 hours ago
Maxim Power Corp. Announces 2026 First Quarter Financial and Operating Results
3 hours ago
Signet Jewelers Appoints Jeffrey Gennette to Its Board
3 hours ago
Rollins To Host 2026 Investor and Analyst Conference on May 14th
3 hours ago
Steep Hill Announces Consolidation and Name Change
3 hours ago
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
3 hours ago
Published May 14 2021
5 min read
Press Release May 14 2021
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg".